A kind of sodium fructose diphosphate oral solution and preparation method
By encapsulating vesicles of fructose sodium diphosphate, the degradation characteristics of amphiphilic block copolymers are used to solve the stability of fructose sodium diphosphate in aqueous solution, and achieve rapid release and efficient therapeutic effects.
Patent Information
- Application Number
- CN202310471336.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-27
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-04-27
AI Technical Summary
The stability of fructose sodium diphosphate in aqueous solution is poor, resulting in a decrease in effective content and an increase in impurities, and the release effect after cyclodextrin is inclusive, affecting the efficacy of the drug.
Vesicles are used to encapsulate fructose sodium diphosphate. The vesicles are composed of amphiphilic block copolymers containing hydrophilic and hydrophobic chain segments. The hydrophilic chain segment contains at least polyamino acids. The hydrophobic chain segment is a biodegradable material. The degradation of vesicle structure in the gastrointestinal intestines achieves rapid release of fructose sodium diphosphate.
It significantly improves the storage stability of the oral solution of fructose sodium diphosphate, and quickly releases drugs in the gastrointestinal and intestines to achieve therapeutic effects, while degrading the product is harmless to the human body.
Smart Images

Figure BDA0004204090700000061 
Figure BDA0004204090700000071
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of pharmaceutical preparations, and in particular to an oral sodium fructose diphosphate solution and a preparation method thereof. Background Art
[0002] Sodium fructose diphosphate is commonly used in clinical treatment of coronary heart disease, angina pectoris, myocardial infarction, cerebral infarction, shock, etc. Sodium fructose diphosphate aqueous solution oral preparation has the characteristics of easy use, but sodium fructose diphosphate has poor stability in aqueous solution, and will gradually deteriorate with the extension of storage time, resulting in reduced effective content and increased impurities. The prior art discloses a method for cyclodextrin inclusion of sodium fructose diphosphate and prepares it into an oral solution preparation, which significantly improves the stability of sodium fructose diphosphate oral solution. However, the molecular structure of cyclodextrin is hydrophobic inside and hydrophilic outside, and sodium fructose diphosphate has good hydrophilicity. Therefore, when sodium fructose diphosphate is included by cyclodextrin, the inclusion effect is not good due to the incompatibility between the hydrophobic property inside the cyclodextrin and the hydrophilic property of sodium fructose diphosphate. Moreover, after the cyclodextrin inclusion of sodium fructose diphosphate enters the human body, sodium fructose diphosphate cannot be quickly released from the cyclodextrin, which affects the performance of the drug effect. Summary of the invention
[0003] In order to solve the above technical problems, the present application provides a sodium fructose diphosphate oral solution and a preparation method.
[0004] This application adopts the following technical solutions:
[0005] A sodium fructose diphosphate oral solution. Every 1000 ml of the sodium fructose diphosphate oral solution comprises: 30-800 g of vesicle-encapsulated sodium fructose diphosphate, 0.1-2 g of a preservative, 0.1-10 g of a flavoring agent, and the balance is water.
[0006] Preferably, the vesicle is composed of an amphiphilic block copolymer containing a hydrophilic segment and a hydrophobic segment, and the hydrophilic segment contains at least polyamino acid.
[0007] More preferably, the hydrophobic segment is a biodegradable material.
[0008] More preferably, the amphiphilic block copolymer is selected from one of PCL-b-PGA, PLA-b-PGA, mPEG-b-PCL-b-PGA, PAMAM-b-PGA and PBAT-b-PGA.
[0009] Preferably, the preservative is selected from one or a combination of benzoic acid and its salts, sorbic acid and its salts, paraben preservatives, benzalkonium bromide and chlorhexidine acetate.
[0010] Preferably, the flavoring agent is selected from one or a combination of aspartame, proteose, sucralose and saccharin sodium.
[0011] The method for preparing the sodium fructose diphosphate oral solution described in any of the above embodiments comprises: adding the amphiphilic block copolymer corresponding to the vesicles into the sodium fructose diphosphate aqueous solution to dissolve and incubate, and then adding the preservative and the flavoring agent to obtain the solution.
[0012] Preferably, the weight ratio of the amphiphilic block copolymer to the sodium fructose diphosphate in the sodium fructose diphosphate aqueous solution is 1-10:100.
[0013] Preferably, the pH of the sodium fructose diphosphate aqueous solution is 3.0-5.0.
[0014] Preferably, after the incubation and before the addition of the preservative, the method further comprises the step of dialysis.
[0015] In summary, this application has the following beneficial effects:
[0016] 1. The present application proposes a new method of encapsulating sodium fructose diphosphate with vesicles to separate sodium fructose diphosphate from the aqueous solution, thereby significantly improving the storage stability of the sodium fructose diphosphate oral solution and preventing the gradual degradation of sodium fructose diphosphate in the aqueous solution, which results in a decrease in the effective content and an increase in the impurity content.
[0017] 2. The vesicles of the present application use amphiphilic block copolymers containing polyamino acids, which can be rapidly degraded under the action of multiple enzymes. Therefore, when the sodium fructose diphosphate oral solution of the present application enters the stomach, the polyamino acids in the vesicle structure are rapidly degraded under the action of multiple enzymes, the vesicle structure is damaged, and the encapsulated sodium fructose diphosphate is rapidly released into the stomach to achieve a therapeutic effect.
[0018] 3. The amino acids formed when the polyamino acid segments in the vesicle structure of the present application are degraded are beneficial to the human body. The biodegradable hydrophobic segments have good compatibility with human tissues and form degradation products that are harmless to the human body after degradation. DETAILED DESCRIPTION
[0019] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below.
[0020] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.
[0021] On the one hand, the present application provides a sodium fructose diphosphate oral solution. Each 1000 ml of the sodium fructose diphosphate oral solution comprises: 30-800 g of vesicle-encapsulated sodium fructose diphosphate, 0.1-2 g of a preservative, 0.1-10 g of a flavoring agent, and the remainder is water.
[0022] Vesicles are molecular ordered compositions with a closed double-layer structure that are spontaneously formed when an amphiphilic surfactant is dispersed in water. The inner layer of the vesicle is hydrophilic, the middle layer is hydrophobic, and the outer layer is hydrophilic. The present application uses vesicles to encapsulate sodium fructose diphosphate, and the hydrophilic sodium fructose diphosphate is encapsulated in the internal cavity of the vesicle, thereby achieving the separation of sodium fructose diphosphate from the aqueous solution, avoiding the decomposition of sodium fructose diphosphate, and improving the stability of the sodium fructose diphosphate oral solution.
[0023] In the sodium fructose diphosphate oral solution of the present application, the weight of the sodium fructose diphosphate encapsulated by the vesicles can be determined according to the disease to be treated. More preferably, the weight of the sodium fructose diphosphate encapsulated by the vesicles can be 100-600 g.
[0024] In a preferred embodiment of the present application, the vesicle is composed of an amphiphilic block copolymer containing a hydrophilic segment and a hydrophobic segment, and the hydrophilic segment contains at least polyamino acid (such as polyaspartic acid PASP, polyglutamic acid PGA, polylysine PLYS, polylysine PTrp, etc.). The amphiphilic block copolymer that can form the vesicle can contain only one hydrophilic segment, or two or more hydrophilic segments, but at least contain a polyamino acid hydrophilic segment, that is, when the amphiphilic block copolymer contains only one hydrophilic segment, the hydrophilic segment is a polyamino acid, and when the amphiphilic block copolymer contains two or more hydrophilic segments, at least one of the hydrophilic segments is a polyamino acid. Using polyamino acids as hydrophilic segments, when the oral solution enters the stomach, the protease in the stomach can quickly degrade the polyamino acids, so that the structure of the vesicle is destroyed and decomposed, and the wrapped sodium fructose diphosphate is released into the stomach to play a therapeutic effect.
[0025] In a more preferred embodiment of the present application, the hydrophobic segment is a biodegradable material. The hydrophobic segment is made of a biodegradable material, such as PCL, PLA, PBAT, polytetramethylene furan (PTMG), etc., which has good biocompatibility, and the degradation products are water, carbon dioxide, etc.
[0026] In the present application, in order to better form vesicles, the average degree of polymerization of the hydrophobic segment in the amphiphilic block copolymer is no more than 10 higher than the average degree of polymerization of the hydrophilic segment. Assuming that the average degree of polymerization of the hydrophobic segment is x and the average degree of polymerization of the hydrophilic segment is y, then 20≤x≤100, 20≤y≤100, 0.6y≤x≤y+10.
[0027] In a more preferred embodiment of the present application, the amphiphilic block copolymer is selected from one of PCL-b-PGA, PLA-b-PGA, mPEG-b-PCL-b-PGA, PAMAM-b-PGA and PBAT-b-PGA.
[0028] In a preferred embodiment of the present application, the preservative is selected from one or a combination of benzoic acid and its salts, sorbic acid and its salts, paraben preservatives, benzalkonium bromide and chlorhexidine acetate.
[0029] In a preferred embodiment of the present application, the flavoring agent is selected from one or a combination of aspartame, proteose, sucralose and saccharin sodium.
[0030] On the other hand, the present application proposes a method for preparing the sodium fructose diphosphate oral solution described in any of the above embodiments, comprising: adding the amphiphilic block copolymer corresponding to the vesicles into the sodium fructose diphosphate aqueous solution to dissolve and incubate, and continuing to add preservatives and flavoring agents to obtain the solution.
[0031] In the above preparation method, sodium fructose diphosphate is first prepared into an aqueous solution, and then the amphiphilic block copolymer is added. The amphiphilic block copolymer self-assembles in the aqueous solution to form vesicles, which continuously coat the sodium fructose diphosphate and finally completely encapsulate the sodium fructose diphosphate. In the present application, the incubation time can be 1-24 hours.
[0032] In a preferred embodiment of the present application, the weight ratio of the amphiphilic block copolymer to the sodium fructose diphosphate in the sodium fructose diphosphate aqueous solution is 1-10: 100. More preferably, the weight ratio of the amphiphilic block copolymer to the sodium fructose diphosphate in the sodium fructose diphosphate aqueous solution is 1-20:80, for example, the weight ratio can be 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, 1:50, 1:55, 1:60, 1:65, 1:70, 1:75, 1:80, etc.
[0033] In a preferred embodiment of the present application, the pH of the sodium fructose diphosphate aqueous solution is 3.0-5.0.
[0034] In a preferred embodiment of the present application, after incubation and before adding the preservative, the method further comprises the step of dialysis. The molecular weight cut-off of the dialysis bag used for dialysis can be 500-2000, the dialysis medium can be water, and the dialysis time can be 24-120 hours.
[0035] The technical solution of the present application is described in detail below in conjunction with embodiments, comparative examples and the like.
[0036] Example 1
[0037] Each 1000 ml of sodium fructose diphosphate oral solution contains: 100 g vesicle-encapsulated sodium fructose diphosphate, 0.3 g potassium benzoate, 1 g aspartame, and the balance is water.
[0038] The weight ratio of amphiphilic block copolymer PCL(47)-b-PGA(46) (the number after the polymer segment represents the average degree of polymerization) to sodium fructose diphosphate is 1:25. Sodium fructose diphosphate is added to water to prepare a sodium fructose diphosphate aqueous solution, the amphiphilic block copolymer is added, stirred at 300 rpm until dissolved, and stirring is continued for 3 hours, potassium benzoate and aspartame are added, stirred to dissolve, and sodium fructose diphosphate oral solution is obtained.
[0039] Example 2
[0040] In Example 1, the amphiphilic block copolymer was added, stirred at 300 rpm until dissolved, and stirred for 3 hours, and then the step of placing in a dialysis bag with a molecular weight cutoff of 1200 for 72 hours was added. After that, potassium benzoate and aspartame were added. The other steps remained unchanged.
[0041] Example 3
[0042] Each 1000 ml of sodium fructose diphosphate oral solution contains: 300 g of vesicle-encapsulated sodium fructose diphosphate, 0.6 g of sodium sorbate, 2 g of sucralose, and the balance is water.
[0043] The weight ratio of the amphiphilic block copolymer PCL(47)-b-PGA(46) to sodium fructose diphosphate is 1:40. Sodium fructose diphosphate is added to water to prepare a sodium fructose diphosphate aqueous solution, the amphiphilic block copolymer is added, stirred at 300 rpm until dissolved, and continued to stir for 6 hours, placed in a dialysis bag with a molecular weight cutoff of 1200 for 72 hours, sodium sorbate and sucralose are added, stirred and dissolved, and sodium fructose diphosphate oral solution is obtained.
[0044] Example 4
[0045] Each 1000ml of sodium fructose diphosphate oral solution contains: 500g vesicle-encapsulated sodium fructose diphosphate, 1g potassium benzoate, 2g sucralose, and the balance is water.
[0046] The amphiphilic block copolymer PTMG-b-PGA was prepared according to the method of Example 1 of the Chinese authorized invention patent CN111072954B. The weight ratio of PTMG-b-PGA to sodium fructose diphosphate was 1:60. Sodium fructose diphosphate was added to water to prepare a sodium fructose diphosphate aqueous solution, PTMG-b-PGA was added, and stirred at 300 rpm until dissolved, and stirring was continued for 10 hours, and dialyzed in a dialysis bag with a molecular weight cutoff of 1200 for 96 hours, potassium benzoate and sucralose were added, and stirred to dissolve, and sodium fructose diphosphate oral solution was obtained.
[0047] Example 5
[0048] Each 1000 ml of sodium fructose diphosphate oral solution contains: 750 g vesicle-encapsulated sodium fructose diphosphate, 1.2 g potassium benzoate, 2 g sucralose, and the balance is water.
[0049] In Example 3, the weight ratio of PTMG-b-PGA to sodium fructose diphosphate is 1:75. Sodium fructose diphosphate is added to water to prepare a sodium fructose diphosphate aqueous solution, PTMG-b-PGA is added, stirred at 300 rpm until dissolved, and stirring is continued for 16 hours, placed in a dialysis bag with a molecular weight cutoff of 1200 for 80 hours, potassium benzoate and sucralose are added, stirred and dissolved, and a sodium fructose diphosphate oral solution is obtained.
[0050] Example 6
[0051] Each 1000 ml of sodium fructose diphosphate oral solution contains: 400 g of vesicle-encapsulated sodium fructose diphosphate, 0.7 g of potassium sorbitol, 2 g of sucralose, and the balance is water.
[0052] The weight ratio of amphiphilic block copolymer PLA(41)-b-PGA(50) to sodium fructose diphosphate is 1:50. Sodium fructose diphosphate is added to water to prepare a sodium fructose diphosphate aqueous solution, the amphiphilic block copolymer is added, stirred at 300 rpm until dissolved, and continued to stir for 15 hours, placed in a dialysis bag with a molecular weight cutoff of 1200 for 72 hours, potassium sorbate and sucralose are added, stirred and dissolved, and sodium fructose diphosphate oral solution is obtained.
[0053] Example 7
[0054] Each 1000 ml of sodium fructose diphosphate oral solution contains: 550 g of vesicle-encapsulated sodium fructose diphosphate, 0.7 g of potassium sorbitol, 2 g of sucralose, and the balance is water.
[0055] The weight ratio of amphiphilic block copolymer PLA(41)-b-PGA(50) to sodium fructose diphosphate is 1:45. Sodium fructose diphosphate is added to water to prepare a sodium fructose diphosphate aqueous solution, the amphiphilic block copolymer is added, stirred at 300 rpm until dissolved, and stirring is continued for 20 hours, potassium sorbate and sucralose are added, stirred and dissolved, and sodium fructose diphosphate oral solution is obtained.
[0056] Example 8
[0057] In Example 7, the amphiphilic block copolymer was added, stirred at 300 rpm until dissolved, and stirred for 20 hours, and then the step of placing in a dialysis bag with a molecular weight cutoff of 1200 for 78 hours was added. Thereafter, potassium sorbate and sucralose were added. The remaining steps remained unchanged.
[0058] Blank control 1: Dissolve 300 g of sodium fructose diphosphate standard in water to prepare 1000 ml of aqueous solution, and adjust the pH of the aqueous solution to 4.0 with dilute hydrochloric acid.
[0059] Blank control 2: 3.85 g of the amphiphilic block copolymer PCL(47)-b-PGA(46) of Example 1 was added to water, stirred and mixed evenly, and 0.3 g of sodium benzoate and 1 g of aspartame were added, stirred evenly, and a 1000 ml solution was prepared.
[0060] Performance test standard curve: sodium fructose diphosphate standard was used to prepare samples with concentrations of 0.01 mg / ml, 0.05 mg / ml, 0.1 mg / ml, 0.5 mg / ml, 1 mg / ml and 2 mg / ml, respectively, and the pH was adjusted to 4.0 with hydrochloric acid, and the absorbance at a wavelength of 292 nm was tested by UV-visible spectrophotometer. Deionized water plus dilute hydrochloric acid was adjusted to pH 4.0 as a blank control to obtain a standard curve with a correlation R=0.9952.
[0061] Stability: 100 ml of the sodium fructose diphosphate oral solution of Examples 1-8 and blank control 1 were sealed and placed at 40°C for 1 month, 3 months and 6 months. Samples were taken and diluted to a sodium fructose diphosphate content of 0.15 mg / ml, and the pH was adjusted to 4.0 with dilute hydrochloric acid. The absorbance at a wavelength of 292 nm was tested using an ultraviolet spectrophotometer. The relative concentration of sodium fructose diphosphate was determined by comparing the above standard curve. The sodium fructose diphosphate concentration at month 0 was used as a benchmark (100%). Three samples were measured at each time and the average value was taken. Blank control 2 was diluted to a concentration of 0.008 mg / ml and diluted hydrochloric acid was added to adjust the pH to 4.0 as a blank control.
[0062] Degradability: 1 ml of each of the oral sodium fructose diphosphate solutions of Examples 1, 3 and 5 was added to 100 ml of artificial gastric juice at 37°C, and 5 ml was sampled at 0 min, 5 min, 10 min, 30 min and 60 min, and alkali was immediately added to adjust the pH to neutral to extinguish the protease. The solution was filtered and the relative percentage of sodium fructose diphosphate was measured by a UV-visible spectrophotometer, with the percentage of sodium fructose diphosphate at 0 min as the benchmark (100%).
[0063] The results are shown in Table 1.
[0064] Table 1
[0065]
[0066]
[0067] It can be seen from the data in Table 1 that the sodium fructose diphosphate oral solution of the present application has good stability, and when entering the gastric juice, the sodium fructose diphosphate can be rapidly released due to the degradation of the polyamino acids on the vesicle structure by pepsin, which destroys the vesicle structure.
[0068] This specific embodiment is merely an explanation of the present application and is not a limitation of the present application. After reading this specification, those skilled in the art may make modifications to the present embodiment without any creative contribution as needed, but such modifications are protected by the patent law as long as they are within the scope of the claims of the present application.
Claims
1. A sodium fructose diphosphate oral solution, characterized in that: Each 1000 ml of the sodium fructose diphosphate oral solution contains: 30-800 g of vesicle-encapsulated sodium fructose diphosphate, 0.1-2 g of a preservative, 0.1-10 g of a flavoring agent, and the balance is water; The vesicle is composed of an amphiphilic block copolymer containing a hydrophilic segment and a hydrophobic segment, wherein the hydrophilic segment contains at least polyamino acid; The hydrophobic segment is a biodegradable material; The amphiphilic block copolymer is selected from one of PCL-b-PGA, PLA-b-PGA and PTMG-b-PGA.
2. The fructose sodium diphosphate oral solution according to claim 1, characterized in that: The preservative is selected from one or a combination of benzoic acid and its salts, sorbic acid and its salts, paraben preservatives, benzalkonium bromide and chlorhexidine acetate.
3. The fructose sodium diphosphate oral solution according to claim 1, characterized in that: The flavoring agent is selected from one or a combination of aspartame, proteose, sucralose and saccharin sodium.
4. The method for preparing the sodium fructose diphosphate oral solution according to any one of claims 1 to 3, characterized in that: include: The amphiphilic block copolymer corresponding to the vesicle is added into a sodium fructose diphosphate aqueous solution to dissolve and incubate, and then the preservative and the flavoring agent are added to obtain the vesicle.
5. The method for preparing the fructose sodium diphosphate oral solution according to claim 4, characterized in that: The weight ratio of the amphiphilic block copolymer to the sodium fructose diphosphate in the sodium fructose diphosphate aqueous solution is 1-10:
100.
6. The method for preparing the fructose sodium diphosphate oral solution according to claim 4, characterized in that: The pH of the sodium fructose diphosphate aqueous solution is 3.0-5.
0.
7. The method for preparing the fructose sodium diphosphate oral solution according to claim 4, characterized in that: After the incubation and before the addition of the preservative, the method further comprises the step of dialysis.
